Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Oncolytics Biotech ( (TSE:ONC) ).
On May 14, 2025, Oncolytics Biotech Inc. released its financial results for the first quarter ending March 31, 2025. The company reported a net loss of $6.7 million, a slight improvement from the $6.9 million loss in the same period last year. Despite the loss, the company’s financial position remains stable with total assets of $19.7 million. The report highlights a decrease in research and development expenses, which contributed to the reduced net loss. This financial update provides stakeholders with insights into the company’s ongoing efforts to manage costs while advancing its cancer treatment programs.
The most recent analyst rating on (TSE:ONC) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the TSE:ONC Stock Forecast page.
Spark’s Take on TSE:ONC Stock
According to Spark, TipRanks’ AI Analyst, TSE:ONC is a Neutral.
Oncolytics Biotech faces significant financial challenges with persistent operational losses and reliance on external funding. Although technical indicators suggest bearish momentum, clinical advancements in cancer treatments provide some optimism. The valuation reflects the speculative nature of biotech investments, with no revenue and negative P/E. Recent earnings call and corporate events offer potential upside through strategic developments but are overshadowed by leadership transitions and market value concerns. Overall, the stock remains speculative with potential upside contingent on successful clinical outcomes.
To see Spark’s full report on TSE:ONC stock, click here.
More about Oncolytics Biotech
Oncolytics Biotech Inc. operates in the biotechnology industry, focusing on the development of pharmaceutical products for cancer treatment. The company is known for its innovative approaches in oncology, particularly through the use of viruses to target and destroy cancer cells.
Average Trading Volume: 71,806
Technical Sentiment Signal: Sell
Current Market Cap: C$63.95M
Find detailed analytics on ONC stock on TipRanks’ Stock Analysis page.